All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.
The abstract (#7506) was presented by Dr Thomas E Witzig of the Mayo Clinic Cancer Center in Rochester, MN.
PILLAR2 (NCT00790036) is a randomized, double-blind, multicenter, phase III study investigating everolimus (EVE) adjuvant therapy versus placebo (PBO) in patients with stage III/IV poor-risk (IPI ≥3) Diffuse Large B-Cell Lymphoma (DLBCL) who have achieved a complete response with first-line rituximab-chemotherapy.
Patients were randomized 1:1 to receive either EVE 10mg/day or PBO for 12 months or until disease relapse, unacceptable toxicity, or death.
The primary outcome measure of PILLAR2 was Disease Free Survival (DFS). The secondary outcome measures were Overall Survival (OS), Lymphoma-Specific Survival (LSS), and a comparison of the safety profiles of EVE versus PBO. LSS is the time from randomization to death caused by lymphoma. The trial began in July 2009, and 742 patients were randomized.
EVE vs PBO |
|
DFS* |
|
Overall (n = 742) |
0.92 (0.69–1.22)† |
IPI 4–5 (n = 313) |
0.65 (0.42–1.01) |
Male (n = 372) |
0.68 (0.45–1.05) |
OS* |
|
Overall (n = 742) |
0.75 (0.51–1.10) |
IPI 4–5 (n = 313) |
0.63 (0.37–1.07) |
Male (n = 372) |
0.55 (0.32–0.94) |
LSS* (n = 742) |
0.64 (0.39–1.04) |
Adjuvant EVE for 1 year did not improve DFS when compared to PBO in IPI 4–5 PET-CR after R-CHOP patients with DLBCL. However, improved OS and LSS were observed with adjuvant EVE compared with PBO. Moreover, adjuvant EVE demonstrated its known safety profile; no new safety concerns were observed. Thomas E Witzig concluded that additional exploration into adjuvant EVE therapy for high-risk DLBCL should be undertaken; as well as other studies investigating the risk-benefit of other adjuvants. Lastly, it was hypothesized that a potential new therapeutic approach would be to combine front-line R-CHOP with everolimus.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox